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ABSTRACT

treatment of cardiac disease are areas of active research. Organisms of mammalian origin
are predominantly chosen for studying cardiac disease and include baboons, pigs, sheep,
dogs, rabbits, rats, and mice (Hasenfuss, 1998). Mammals are typically used due to their
similarity in physiology, making them candidates to research new treatment methods
(Patel et al., 2001). Smaller mammals, such as rats and mice, are also useful because
they can be genetically manipulated and subsequently used to determine the effects of
mutations in genes relating to cardiac function (Rosenthal and Brown, 2007). Similarly,
zebrafish have recently emerged as another model for human cardiac disease research
and have been used to model congenital heart defects and cardiomyopathies, as well as
to determine mechanisms that can lead to cardiac disease (Bakkers, 2011).

Background
Current animal models of human cardiac disease may be similar in anatomy and
physiology but are often expensive and tedious to work with. The current need is for a
model organism that is more efficient to work with in the lab but that still provides an
accurate model of human cardiac disease. Drosophila melanogaster (D. mel) is such a
candidate. While 74% of the genes coding for protein are conserved between D. mel and
human hearts, it is unknown if cardiac medication used in humans, such as atropine and
propranolol hydrochloride, similarly affect heart rate. I hypothesized that administration
of atropine and propranolol hydrochloride to third instar larvae would cause an increase
and decrease respectively in the heart rates of D. mel.
Methods
After larvae hatched and reached the second instar larval phase, they were moved to
fresh vials. The control group larvae were transferred to vials containing no medication,
and the experimental group larvae were transferred to vials with 1mM atropine or
1mM propranolol hydrochloride. The larvae inhabited the new vials for twenty-four
hours to reach the third instar larvae stage. Larvae were removed, placed individually
on a microscope slide, and observed using the 4X objective lens of a Leica compound
microscope. Heart rates of fifty larvae per group were recorded in triplicate over fifteen
second intervals.
Results
We observed elevated heart rates of 406 ± 3.18 beats per minute in atropine treated larvae
when compared to rates of 388 ± 2.07 in control larvae, a 4.83% increase. Moreover,
heart rates were slowed to an average of 274 ± 2.70 beats per minute in propranolol
hydrochloride treated hearts, a 29.18% decrease. Both changes in heart rate when
compared to the control were found to be statistically significant (p<0.001).
Conclusion
Administration of propranolol hydrochloride and atropine increased and decreased the
heart rates of D. mel respectively. This data supports the hypothesis that D. mel can serve
as an experimental model for human cardiovascular disease. Future work should build on
this study and focus on the use of D. mel in preliminary pharmaceutical testing for new
medication treating cardiovascular conditions.
Keywords: drosophila melanogaster, atropine, propranolol hydrochloride, heart rate
INTRODUCTION
Models of Cardiovascular Disease
According to the American Heart Association, one American dies of cardiac disease
every forty seconds (Mozaffarian et al., 2015), and the causation, prevention, and
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These organisms have been pivotal in developing current knowledge regarding the
physiology of the human cardiovascular system as well as the development and treatment
of cardiovascular disease. Unfortunately, many of these organisms are inefficient to use
in the laboratory. Costs to obtain and maintain these organisms in a laboratory setting are
not trivial. According to the Jackson Laboratory website, purchasing mice for research
would cost approximately $10.75 per mouse (“Jax mice pricing information,” 2018).
Genetically modified mice are even more expensive, and, according to the Cyagen
Biosciences website, could range from $250 to nearly $7,000 depending on the desired
method of inserting genes into the mouse genome (“Regular transgenic mice,” 2018).
Rabbits, according to the Charles River website, range from $160 to $330 per rabbit
depending on weight (“New Zealand white rabbit,” 2018). In addition, many of these
animals can be difficult to handle and manage within the lab to ensure they are cared for
humanely throughout research. Mice, for example, can move quickly and may attempt
to bite the hands of researchers while handling (Buerge and Weiss, 2004). Dogs and
primates, according to the Johns Hopkins University Animal Care and Use Committee,
may require tranquilization if they are aggressive and difficult to work with. To advance
research in this area, it would be advantageous to find an organism that is more efficient
to utilize in the lab but that still provides an accurate model of human cardiac disease.
Drosophila melanogaster
D. mel is a candidate for modeling human cardiac disease and is an efficient organism
to use in the lab for many reasons. One reason is the well documented short lifespan of
the organism (Linford et al., 2013). D. mel is used as a model of aging due to its short
life span of approximately fifty days from fertilization of the egg to the death of the
adult fly. This lifespan is significantly lower than those of typical mammals. A rat, for
example, has an estimated mean life expectancy of twenty-two months (Baati et al.,
2012). A shorter lifespan allows researchers to study organisms in different stages of
life over a shorter amount of time.
Another contributor to the efficiency of using D. mel is the immense research that
has been done to sequence the genome of the organism (Pandey and Nichols, 2011).
Scientists know many of the genes in the DNA of D. mel and are thus able to use this
information to determine whether genes code for disease or for resistance to disease.
Further, D. mel can incur mutations in genes homologous to genes of human disease
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naturally or by manipulation (Bier and Bodmer, 2004). This ability allows D. mel to be
a model for discovering the outcome of mutations in genes necessary for physiological
function and maintenance of health.

In a study identifying the genetic components of heart development and function, it
was noted that the D. mel heart has only one chamber, referred to as the cardiac tube,
and lacks coronary arteries (Seyres, Röder, and Perrin, 2012). This structure is different
than that of a human heart, in which there are four highly vascularized chambers.
Another study notes that the D. mel heart has only one layer of cardiomyocytes (heart
cells) whereas the human heart has two sections of cardiomyocytes, the myocardium
and endocardium (Medioni et al., 2009). Despite the anatomical differences though,
the similarity in genetics and proteome present a convincing case for D. mel as a model
of human cardiovascular disease.

Further benefits include the feasibility of raising the organisms in lab and the inexpensive
cost (Doke and Dhawale, 2015). D. mel, in contrast to the prices of mammalian models,
can be purchased for $8.10 per vial containing twenty-five to thirty flies for most
wildtype and mutant strains. In addition, all of the materials necessary for culturing
can be purchased for $65.50 (“Carolina easy fly drosophila cultures, living,” 2018).
In addition to being a practical organism to work with, D. mel is a candidate for human
cardiac disease research. A study performed by Cammarato et al. (2011) determined
that the proteome, or complete protein makeup, of the D. mel heart contains 498 genes
vital to heart function. Seventy-four of these genes (15%) were protein products that
are also produced in humans. Additionally, 73% of the genes were determined to be
orthologs of genes found in humans and mice. Other experiments researching the
genetic makeup of the D. mel heart have shown that they are physiologically similar
to human hearts. The hearts of D. mel can develop structural defects and suffer from
arrhythmias (irregular heartbeats) or cardiomyopathies (hereditary cardiac disease)
(Pandey and Nichols, 2011). Another study used D. mel to model the development
of age-related heart failure (Ocorr, Akasaka, and Bodmer, 2007). Due to genetic
similarity, D. mel hearts develop heart failure caused by errors in pacing as well as
arrhythmias, key factors in researching age-related heart failure. This research suggests
that D. mel has a promising future in determining genetic contributions to cardiac
disease. Anatomically, however, the heart of D. mel is different from that of a human
(Figure 1).
Figure 1: D. mel cardiac
tube captured during the
recording of heart rate.
The image was taken of a
D. mel larvae under the 4X
objective lens of a Leica
compound microscope. The
outline of the head of the
cardiac tube can be observed.
Surrounding the cardiac
tube is a single layer of
cardiomyocytes.

Despite current advances in understanding genomic similarities between D. mel
and other organisms typically used as models, it is still not known whether the D.
mel cardiovascular system is capable of responding similarly to heart medication.
Understanding physiological responses of the D. mel heart to heart medication could
further qualify it as a model of human cardiovascular disease and open new doors of
research.
Atropine
Atropine is frequently prescribed to increase heart rate in instances of hypotension
(“Atropine,” 2014). The drug is administered to those suffering from bradycardia, a
condition of extremely low heart rate to increase firing of the SA node in the heart (Al,
2014).
Atropine increases heart rate in humans by preventing acetylcholine from binding to
sinoatrial and atrioventricular nodes. It does this by blocking muscarinic acetylcholine
receptors (mAchRs) and, as a result, contraction of these pacemaking nodes increases
(Kinkade, 2012). For this drug to effect D. mel in a similar fashion, the organism must
have conserved receptors with the same capability of being blocked by atropine. One
study determined which G-protein receptors in D. mel were coupled to mAchRs, the
active site of atropine (Ren, Folke, Hauser, Li, and Grimmelikhuijzen, 2015). They
found that mammals have five mAchRs and that D. mel has only two, an A-type and
B-type. Specifically, the A-type mAchRs in D. mel were determined to have a similar
structure to the mammalian receptors. For these receptors to function similarly to human
mAchRs, the D. mel heart would need to be similarly innervated. It was originally
thought that the D. mel heart was not innervated. It was discovered, however, that the
D. mel heart is indeed innervated (Dulcis and Levine, 2003). At the larval stage, heart
rate is controlled by a pacemaker structure thought to be located in the caudal region
of the heart. With all of this in mind, it is still not known whether these receptors
can invoke the same response on the innervating structure of the D. mel heart. If the
mAchRs of D. mel can respond to atropine similarly to humans, this would support our
knowledge of D. mel as a model for human cardiac disease and medicinal research.
Propranolol hydrochloride
While the effect of atropine increases heart rate, propranolol hydrochloride is a
β-blocker that decreases heart rate and is prescribed by physicians for patients suffering
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from heart failure (Coppola, Froio, and Chiumello, 2015). Results of one study suggest
that β-blockers benefit patients by reducing heart rate and thereby inducing relaxation
which may have an effect on diastolic filling of the heart (Dobre et al., 2007).

fresh vials that contained the experimental treatment. For the control group, fifty second
instar larvae were moved to vials containing media made with sterile deionized water.
For the first experimental group, fifty second instar larvae were transferred to vials with
1mM propranolol hydrochloride in the media. For the second experimental group, fifty
second instar larvae were transferred to vials with 1mM atropine in the media. 1mM
concentrations of each medication were utilized after performing a preliminary test of
a tenfold range of molar concentrations, of which 1mM concentrations were found to
display an effect on heart rate without mortality of the larvae. The second instar larvae
inhabited the new vials for twenty-four hours, maturing into third instar larvae during this
time at which point heart rates were observed.

β-blockers reduce heart rate by blocking beta1-adrenergic receptors (βARs), reducing
sinoatrial node automaticity and therefore heart rate (Gibson and Raphael, 2014). A
study measuring the effects of βARs agonists versus antagonists on D. mel showed that
antagonist β-blockers, such as propranolol hydrochloride, decreased mortality by 6.4%
(Spindler et al., 2013). The same study also showed that D. mel does not have βARs but
possesses a family of G-protein receptors that are structurally and functionally related
to βARs. However, it is not known whether treatment with propranolol produces an
effect on heart rate. If the βAR-like receptors in D. mel can respond to propranolol
hydrochloride in a similar way to humans, this would further support D. mel as a model
for human cardiac disease and medicinal research.
The Effects of Heart Medication on D. mel
While there is proteomic support for a conserved mechanism of regulation, it is unknown
if heart medications such as atropine and propranolol hydrochloride have a similar
effect on heart rate. We hypothesized that atropine and propranolol hydrochloride in the
growth media of third instar larvae would cause an increase and decrease respectively
in the heart rates of D. mel. Characterization of the pharmacologic activity of these
two drugs on D. mel cardiac activity would further clarify if there are conserved
mechanisms of heart rate regulation between the invertebrate D. mel and mammals
and would lend further support to using D. mel as a model for human cardiac disease.
METHODS
Materials and D. mel Culturing
Wild type D. mel were purchased from Carolina Biological and atropine and propranolol
hydrochloride were purchased from Sigma Aldrich. To maintain a constant living
environment, the flies were kept at 22°C and transferred to new vials to mate. The
vials were made by mixing equal amounts of Instant Drosophila Medium purchased
from Carolina Biological with sterile deionized water in drosophila culturing vials with
sponge plugs. The flies were given several days to lay eggs, and once larvae were seen
in the vials the adults were moved to new vials to repeat the process and obtain stock
vials of adult flies.
Treatment with Atropine and Propranolol Hydrochloride
The experimental procedure required a time span of seven days to complete (Figure 2)
and was completed three times in succession. On the first day, adult flies from stock vials
were placed in three new vials to mate. Over the following four to five days, the adult
flies laid eggs in the medium that hatched into larvae and began to mature. By the sixth
day, the larvae reached the second instar larval phase. Larvae at this stage were preferred
due to their burrowing nature in which they tunnel deep into their growth media, thereby
increasing exposure to medication in the media. Second instar larvae were transferred to
10
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Figure 2: Timeline of procedure detailing when flies were moved to new vials and when heart rates were
recorded. On Day 1, adult flies were moved to new vials to mate. Over the next few days, the flies were left to lay
eggs. Once the larvae hatched from the eggs and entered the second instar larval stage of development, they were
moved to fresh media. At this stage, atropine or propranolol hydrochloride were administered to the media. After
twenty-four hours, the third instar larval heart rates were recorded.

Heart Rate Assessment of Third Instar Larvae
The heart rate of each third instar larvae of the control and treatment groups was observed
three times in fifteen second intervals. Larvae were removed, placed individually on
a microscope slide, and observed using the 4X objective lens of a Leica compound
microscope. Beating hearts were visualized through the transparent skin of the dorsal
side when larvae were placed on their ventral side. Once the microscope was properly
focused on the larva, a fifteen second timer with a ten second interval of rest was
started. A tap counter was used to count the number of times the heart beat during each
fifteen second interval. After a ten second rest, the process was repeated until a total of
three heart rates had been recorded for the larva.
Values were averaged for each larva, with the resulting fifty averages used to calculate
the average heart rate and standard error for the group. To determine the significance
of the two experimental groups from the control group, a T-Test was performed. The
statistical analysis was done using Microsoft Excel.
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RESULTS

The effects of the two medications on the heart rates of D. mel support previous work
that demonstrated the conserved mAchRs and βARs in D. mel. One study determined
the protein content of the two mAchRs found in the D. mel genome (Ren et al., 2015).
They concluded that one of the two mAchRs is pharmacologically similar to that of
humans; however, they did not demonstrate that D. mel was capable of responding
to atropine in a similar way to humans. The increase in heart rate due to atropine
supports this research, further supporting the notion that the mAchRs in D. mel are
pharmacologically similar to human mAchRs. Another study used propranolol
hydrochloride to study the effects of β-blockers on the lifespan of D. mel (Spindler
et al., 2013). In this research, it is explained that D. mel do not have the same βARs
as humans but rather utilize a family of G-protein receptors that may function very
similarly to that of humans. The decrease in heart rate due to propranolol hydrochloride
that was observed in this study would support this research and suggest that the heart
of D. mel has conserved receptors capable of responding to the β-blocker propranolol
hydrochloride in a similar manner to humans.

Second instar D. mel larvae were treated with 1mM atropine or 1mM propranolol
hydrochloride for twenty-four hours, after which the heart rates of fifty larvae were
assessed at the third instar larval stage for each treatment. These averages were compared
to that of untreated control larvae (Figure 3). Atropine treatment resulted in a heart rate
of 406 ± 3.18 beats per minute, which represented a 4.83% increase in heart rate over
control hearts (388 ± 2.07 bpm). On the contrary, propranolol hydrochloride treated
larvae had hearts rates of 275 ± 2.70 beats per minute, which was a 29.18% decrease
in heart rate when compared to controls. Both changes in heart rate were statistically
significant (p<0.001). These results indicate that both heart rate medications influenced
a change in the heart rates of D. mel larvae.
DISCUSSION
This research aimed to test whether D. mel larvae can respond similarly to humans when
treated with heart medication. We observed a significant difference in the heart rates
of the larvae that were treated with propranolol hydrochloride. Control larvae had an
average heart rate of 388 ± 2.07 beats per minute while the propranolol hydrochloride
treated larvae had an average heart rate of 275 ± 2.70 beats per minute (p<0.001). This
supports the hypothesis that propranolol hydrochloride decreases the heart rate of third
instar larvae and demonstrates that D. mel responds to heart medication similarly as
humans. Further, we also observed a difference in the heart rates of the larvae treated
with atropine. Larvae treated with atropine had an increased heart rate of 406 ± 3.18
beats per minute (p<0.001). This supports the hypothesis that atropine increases the
heart rate of third instar larvae and demonstrates that D. mel can respond to heart
medication similarly as humans.
Figure 3: Atropine and
Propranolol Hydrochloride
act as respective positive
and negative chrontropes
of D. mel heart rates.
Average heart rates of treated
third instar larvae in the
control, atropine (1mM), and
propranolol hydrochloride
(1mM) groups were assessed
by observing the heart rate
using the 4X objective
lens of a Leica compound
microscope. Heart rates
were recorded in triplicate
for fifty in each group. Data
are presented as mean plus
and minus the standard error.
Respective increase and
decreases of heart rate due
to atropine and propranolol
hydrochloride treatments
were statistically significant
(p<0.001).
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To evaluate the similarity between the effects of atropine and propranolol on the
heart rates of D. mel larvae and humans, it is necessary to compare the results of
this experiment to those found by other studies. After the administration of atropine,
there was an observed 4.83% increase in larval heart rate. One study, which measured
heart rate after the endobronchial administration of atropine in humans, found a 16%
increase in heart rate at a dosage of 0.02 mg/kg (Paret et al., 1999). The difference
between this 16% increase in heart rate from the observed 4.83% increase in heart
rate is due to differences in atropine dose as well as the method of delivering the
medication. Another study found that atropine increased heart rate in humans by
13.1 beats per minute (bpm) after 80 minutes at a dosage of 0.15 µg/kg/min (Bruck,
Ulrich, Gerlach, Radke, and Brodde, 2003). The difference between the 13.1 bpm
increase from the approximately 18 bmp increase observed in this experiment is due to
differences in dose. There was also an observed 29.18% increase in larval heart rate
after the administration of propranolol hydrochloride. In one study, participants who
received 40mg of propranolol hydrochloride were found to have resting heart rates of
62 bpm after five hours as opposed to 72 bpm in participants who received the placebo
(Joannides et al., 2006). The difference in recorded decrease in heart rate is due to the
difference in dose administered and time between doses. Larvae in this experiment
were exposed to propranolol hydrochloride for twenty-four hours before heart rate was
recorded; however, participants in the study described above were exposed to the drug
for only five hours. This difference in time could influence the observed decrease in
heart rate in the two experiments. Through comparing the results of this experiment
to those of other studies, it is apparent that the effects of the drugs on the heart rates
of D. mel larvae are similar. To confirm this conclusion, future studies need to employ
concentrations of the drugs that more closely parallel those used in human studies.
There were limitations in the study design that should be recognized and improved
upon in future research. Most importantly, the research should have been completed
as a blinded study. This would allow for experimental recording of heart rates while
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unaware of the group being observed. Performing the experiment in this way would
eliminate the possibility of bias. Further, there are more precise methods of recording
heart rate that could have been used. At heart rates as rapid as that of D. mel, human
error in manually counting is inevitable. With additional funding, software could be
purchased which would allow for computer-generated analysis of videos of the beating
larval heart that would more accurately assess the heart rate (Vogler and Ocorr, 2009).
While further research will add to our knowledge in this area, the data collected in
this experiment suggest that the D. mel heart responds to atropine and propranolol
hydrochloride as the human heart does. If this is indeed the case, future research could
be performed to discover whether D. mel has the capability of responding to other
heart medications. In the future, D. mel could be used as a model organism for research
being performed on the effects of these heart medications.
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